NCT04229459 - Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 30, 2019

Primary Completion Date

December 31, 2022

Study Completion Date

June 30, 2027

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG

Cisplatin

Cisplatin 100mg/m2 IV on day 1 of induction chemotherapy, 75mg/m2 IV on day 1 and 29 of chemoradiation

DRUG

5-FU

5-FU 1000mg/m2/d IV on days 1-5 of induction chemotherapy, 1000mg/m2/d IV on days 1-4 and days 29-32 of chemoradiation

RADIATION

Radiation therapy

1.8 Gy/fraction, 5 days a week for a total of 28 days

DRUG

Cetuximab

Cetuximab 400mg/m2 IV on day 1 followed by 250mg/m2 IV weekly on induction chemotherapy, 250mg/m2 IV weekly on chemoradiation, 500mg/m2 IV on day 1 of each treatment cycle, every two weeks during immunotherapy

DRUG

Nivolumab

Nivolumab 3mg/kg IV on day 1 of each treatment cycle, every two weeks during immunotherapy

Trial Locations (1)

Unknown

RECRUITING

Rabin Medical Center, Petah Tikva